Stefan Pulst

Early-stage drug candidate diminishes deficits in Parkinson’s Disease

Chemical compound reduces alpha-synuclein, cell stress.


Gene discovery leads to next-generation experimental therapy for ALS

Efforts to understand the genetics of neurological diseases leads to a potential treatment.